<DOC>
	<DOCNO>NCT01985724</DOCNO>
	<brief_summary>In trial investigator propose assess dose dense , G-CSF support sequential administration 4 cycle FEC follow 4 cycle docetaxel versus 6 cycle docetaxel/cyclophosphamide adjuvant chemotherapy woman HER-2 negative , axillary lymph node positive breast cancer</brief_summary>
	<brief_title>Sequential Administration FE75C Docetaxel Versus Docetaxel/Cyclophosphamide HER-2 Negative , Node Positive Breast Cancer</brief_title>
	<detailed_description>Anthracycline-containing regimen recommend adjuvant treatment woman node positive breast cancer . At least five large randomize clinical trial demonstrate addition sequential administration taxane ( paclitaxel docetaxel ) anthracycline-based regimen result superior clinical outcome woman node positive high risk node-negative early breast cancer . In two large randomize study dose dense administration G-CSF support anthracycline-based paclitaxel combination superior regimen administer every three week without growth factor adjuvant therapy woman axillary node positive breast cancer . In one randomized trial , docetaxel prove superior paclitaxel woman metastatic breast cancer . Data least one trial suggest four cycle non-anthracycline taxane-containing adjuvant regimen ( docetaxel plus cyclophosphamide ) provide outcome least good , good four cycle doxorubicin/cyclophosphamide combination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Women histologicallyconfirmed unilateral invasive ductal lobular breast adenocarcinoma Within 60 day surgical excision primary tumor tumorfree operation margin ; least 10 axillary lymph node remove . Tumor involvement least one axillary lymph node Absence clinical radiological evidence local metastatic disease Premenopausal postmenopausal woman age 1875 year old Adequate bone marrow function ( absolute neutrophil count &gt; 1500/mm3 , platelet count &gt; 100.000/mm3 , hemoglobin &gt; 10gr/mm3 ) Adequate liver ( bilirubin &lt; 1.0 time upper limit normal SGOT/SGPT &lt; 2.5 time upper limit normal ) renal function ( creatinine &lt; 1.5mg/dl ) Adequate cardiac function ( LVEF &gt; 50 % ) Written inform consent Positive pregnancy test . Psychiatric illness social situation would preclude study compliance . Other concurrent uncontrolled illness . Prior concurrent antineoplastic therapy e.g . hormonal therapy , radiation therapy , chemotherapy , biological agent . Previous history invasive malignancy nonmelanomatous skin cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Early breast cancer</keyword>
	<keyword>Axillary node positive</keyword>
	<keyword>HER-2 negative</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Dose dense</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>FEC</keyword>
</DOC>